BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22234693)

  • 1. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD.
    Léon C; Evert K; Dombrowski F; Pertuy F; Eckly A; Laeuffer P; Gachet C; Greinacher A
    Blood; 2012 Apr; 119(14):3333-41. PubMed ID: 22234693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
    Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
    Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
    Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
    Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion.
    Léon C; Eckly A; Hechler B; Aleil B; Freund M; Ravanat C; Jourdain M; Nonne C; Weber J; Tiedt R; Gratacap MP; Severin S; Cazenave JP; Lanza F; Skoda R; Gachet C
    Blood; 2007 Nov; 110(9):3183-91. PubMed ID: 17664350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia.
    Yamanouchi J; Hato T; Kunishima S; Niiya T; Nakamura H; Yasukawa M
    Ann Hematol; 2015 Sep; 94(9):1599-600. PubMed ID: 26051904
    [No Abstract]   [Full Text] [Related]  

  • 6. Developmental differences between newborn and adult mice in response to romiplostim.
    Sparger KA; Ramsey H; Lorenz V; Liu ZJ; Feldman HA; Li N; Laforest T; Sola-Visner MC
    Platelets; 2018 Jun; 29(4):365-372. PubMed ID: 28548028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
    Eckly A; Strassel C; Freund M; Cazenave JP; Lanza F; Gachet C; Léon C
    Blood; 2009 Apr; 113(14):3182-9. PubMed ID: 18984861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of
    Rabbolini DJ; Chun Y; Latimer M; Kunishima S; Fixter K; Valecha B; Tan P; Chew LP; Kile BT; Burt R; Radhakrishnan K; Bird R; Ockelford P; Gabrielli S; Chen Q; Stevenson WS; Ward CM; Morel-Kopp MC
    Platelets; 2018 Dec; 29(8):793-800. PubMed ID: 29090586
    [No Abstract]   [Full Text] [Related]  

  • 9. Importance of environmental stiffness for megakaryocyte differentiation and proplatelet formation.
    Aguilar A; Pertuy F; Eckly A; Strassel C; Collin D; Gachet C; Lanza F; Léon C
    Blood; 2016 Oct; 128(16):2022-2032. PubMed ID: 27503502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
    Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
    J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.
    Eckly A; Rinckel JY; Laeuffer P; Cazenave JP; Lanza F; Gachet C; Léon C
    J Thromb Haemost; 2010 Oct; 8(10):2243-51. PubMed ID: 20695978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
    Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
    J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.
    Lorenz V; Ramsey H; Liu ZJ; Italiano J; Hoffmeister K; Bihorel S; Mager D; Hu Z; Slayton WB; Kile BT; Sola-Visner M; Ferrer-Marin F
    Thromb Haemost; 2017 Dec; 117(12):2322-2333. PubMed ID: 29212120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function.
    Mazharian A; Wang YJ; Mori J; Bem D; Finney B; Heising S; Gissen P; White JG; Berndt MC; Gardiner EE; Nieswandt B; Douglas MR; Campbell RD; Watson SP; Senis YA
    Sci Signal; 2012 Oct; 5(248):ra78. PubMed ID: 23112346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
    Elife; 2021 Jun; 10():. PubMed ID: 34059198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient generation of megakaryocytes from human induced pluripotent stem cells using food and drug administration-approved pharmacological reagents.
    Liu Y; Wang Y; Gao Y; Forbes JA; Qayyum R; Becker L; Cheng L; Wang ZZ
    Stem Cells Transl Med; 2015 Apr; 4(4):309-19. PubMed ID: 25713465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
    Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis.
    Moussa MM; Mowafy N
    J Gastroenterol Hepatol; 2013 Feb; 28(2):335-41. PubMed ID: 22849409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia.
    Spinler KR; Shin JW; Lambert MP; Discher DE
    Blood; 2015 Jan; 125(3):525-33. PubMed ID: 25395423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
    Kuter DJ; Mufti GJ; Bain BJ; Hasserjian RP; Davis W; Rutstein M
    Blood; 2009 Oct; 114(18):3748-56. PubMed ID: 19671919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.